CX-01 Heparin Derivative Investigated for Older Patients With AML

Leggi l'articolo originale


A randomized phase II trial investigated whether adding CX-01, a low anticoagulant heparin derivative, to standard care improves outcomes in older patients with acute myeloid leukemia.

Lascia un commento